Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

26th annual Buyside View sees biotech investors eyeing small- and mid-caps in 2018
BioCentury | Nov 3, 2017
Regulation

Frame work

How FDA is using and improving benefit-risk frameworks in new drug reviews
BioCentury | Sep 29, 2017
Clinical News

Merck discontinues HCV candidates

BioCentury | Dec 15, 2016
Clinical News

Direct-acting antivirals regulatory update

BioCentury | Nov 18, 2016
Clinical News

MK-3682B: Interim Ph II C-SURGE data

BioCentury | Nov 15, 2016
Clinical News

Merck reports HCV triple combo data

BioCentury | Oct 4, 2016
Company News

FDA adds warning to HCV drugs' labels

Items per page:
1 - 10 of 14
Help Center
Username
Request a Demo
Request Training
Ask a Question